{"TechnicalAnalysis":{"title":"NDAQ Final Impulse To 160.08","content":"NDAQ seems to be forming a bullish impulse consisting of primary sub-waves \u2460-\u2461-\u2462-\u2463-\u2464.\r\n\r\nHorizontal correction wave \u2463 has ended as a contracted intermediate triangle.\r\n\r\nWave \u2464 is a potential new bullish impulse, and it has completed intermediate sub-waves (1) and (2).\r\n\r\nIn the short term, we could see an increase in prices until the end of the primary impulse wave \u2464, near 160.08. At that level, it will be at 76.4% of wave \u2462.\r\n\r\n\"ndaq\"<\/a>\r\n\r\nHowever, the alternative option hints at an incomplete primary correction \u2463.\r\n\r\nIn this case, it has a complex double three formation (W)-(X)-(Y).\r\n\r\nMost recently, the bullish intervening wave (X) completed its pattern, which took the form of a minor double zigzag.\r\n\r\nFinally, we could see a drop in prices in the final intermediate wave (Y) to 123.53. The target is on the support line, which is drawn through waves W and \u24d1.\r\n\r\n[sv slug=\"practice-on-demo-test-strategy\"]","date":"2021-01-15 13:00:02","link":"https:\/\/www.orbex.com\/blog\/?p=134074","image":"https:\/\/assets.iorbex.com\/blog\/wp-content\/uploads\/2021\/01\/15105304\/NDAQ1.png","category_url":"https:\/\/www.orbex.com\/blog\/en\/category\/technical-analysis"},"FundamentalAnalysis":{"title":"New Highs For J&J On Vaccine News","content":"

Promising COVID Results<\/strong><\/h2>\r\nShares in US pharmaceutical company Johnson & Johnson are trading higher pre-market on Friday. This comes following further positive news on its COVID vaccine this week which saw the company\u2019s shares gap higher on Thursday.\r\n\r\nJ&J\u2019s shares have been on a firm rally over recent months, trading up off the 134 November lows to the high 160s as of writing. The broad rebound in risk appetite has helped lift sentiment in the company\u2019s stock, reversing the losses seen in response to poor Q3 results.\r\n

Further Data To Be Released<\/strong><\/h2>\r\nThis week, J&J\u2019s COVID vaccine was approved following the release of its vaccine trial data which showed promising results. Unlike the other vaccines in the market, J&J's vaccine is a one-dose treatment that has shown to provide protection across all age groups.\r\n\r\nThe company is due to release further late-stage trial data this month. They are seeking EU and UK regulatory approval in February. It has the aim of delivering the first doses to those regions by April.\r\n

US & EU Secure J&J Drug<\/strong><\/h2>\r\nLast year, the company signed a $1 billion deal with the US government to provide 100 million doses of its one-shot vaccine by mid-2021. However, there are concerns that the company will not be able to fulfill this deadline. This is due to their current manufacturing and supply issues.\r\n\r\nJ&J has warned the government that it has currently fallen behind its production targets and will not catch up until the end of April at the current rate. The drug was initially scheduled to be rolled out in the US in March. However, so far, there has been no sign of this plan being adjusted.\r\n\r\nJohnson and Johnson have now signed a deal with the EU to provide 200 million doses of the drug this year with an option to purchase a further 200 million doses.\r\n\r\nThe company received a $360 million investment from the EU to secure the drug. This included a down payment that will need to be further added to by individual governments looking to roll out the vaccine.\r\n

J&J Hits News Highs<\/strong><\/h2>\r\n\"j&j<\/a>\r\n\r\nJ&J shares continue to trade higher within the bullish channel which has framed the move off the November lows<\/a>. The recent correction within the channel found support at a test of the 157.24 level, sending price higher again.\r\n\r\nPrice is now testing the 161.23 resistance level, having pierced the level to trade new, all-time highs. While price holds above the 157.24 level, the near term bias remains in favor of further upside.\r\n\r\n[sv slug=\"practice-on-demo-test-strategy\"]","date":"2021-01-15 16:19:48","link":"https:\/\/www.orbex.com\/blog\/?p=134110","image":"https:\/\/assets.iorbex.com\/blog\/wp-content\/uploads\/2021\/01\/15144838\/shutterstock_1593023779.jpg","category_url":"https:\/\/www.orbex.com\/blog\/en\/category\/fundamental-analysis"},"Webinars":{"title":"Webinar \"Overtrading - zjawisko, kt\u00f3re niszczy psychik\u0119 i portfele inwestor\u00f3w\"","content":"Transakcja ju\u017c otwarta. Widzisz jak pieni\u0105dze tikaj\u0105 przed Twoimi oczami. Zarabiasz, tracisz, zn\u00f3w zarabiasz, teraz tracisz troch\u0119 wi\u0119cej. Zastanawiasz si\u0119, czy dobrze zrobi\u0142e\u015b, \u017ce w og\u00f3le otworzy\u0142e\u015b t\u0105 pozycj\u0119.\r\n\r\nGdyby\u015b tylko m\u00f3g\u0142 cofn\u0105\u0107 czas\u2026 Czy ta sytuacja wydaje Ci si\u0119 znajoma? Je\u015bli tak, to mog\u0142e\u015b nie\u015bwiadomie pa\u015b\u0107 ofiar\u0105 jednej z najwi\u0119kszych chor\u00f3b, gn\u0119bi\u0105cych trader\u00f3w na Forex \u2013 Overtradingu.\r\n\r\nAgenda spotkania:<\/strong>\r\n1. Zaw\u00f3d - Trader\r\n2. Specyfika rynku FOREX\r\n3. \u201eBariery\u201d wej\u015bcia na rynek\r\n4. Ci\u0105g\u0142e okazje do zarabiania\r\n5. Overtrading \u2013 jak sobie z tym radzi\u0107?\r\n6. Podsumowanie\r\n\r\n[advanced_iframe src=\"https:\/\/www.orbex.com\/en\/webinar-iframe?webinar_id=5108538141735533069&ref_id=pw-1120\" width=\"100%\" height=\"600\"]","date":"2020-11-30","link":"https:\/\/www.orbex.com\/blog\/?p=128671","image":"https:\/\/assets.iorbex.com\/blog\/wp-content\/uploads\/2020\/11\/17145334\/Blog-Post.png","category_url":"https:\/\/www.orbex.com\/blog\/en\/category\/forex-library\/webinars"}}